Photocure fundamentale forhold (PHO)

[Rodjer]

Dessverre, det er ikke mulig for meg hvertfall å se.
Den er nok ikke helt ny, men like relevant og kan ikke huske den er delt noe sted tidligere. Jeg har hvertfall aldri hørt den tidligere.

[cinco]

Er det denne fra 15. mai 2019?

Early detection of bladder cancer available at St. Mary

[cinco]

1. mai ser det ut som i metadataene

[ListeBot]

En fersk aksjonærliste for PHO er tilgjengelig for Insider-medlemmer. Ikke Insider? Les mer og prøv gratis

[Savepig]

UF Urology (UF_Urology)

[pdx]

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

1. @Rodjer (874 likes)

Photocure småprat 2019 (PHO)

Takk.

2. @Savepig (753 likes)

Photocure småprat 2019 (PHO)

En ting som er greit er om vi også.husker å gi Hestdal den kudos han faktisk fortjener her. Det var på hans vakt selskapet startet og gjennomførte fase 3 studie for surveillance:

3. @Snoeffelen (351 likes)

Dette er bare helt konge!!!

Resten av topp 10:

4. @Londonmannen (182 likes)

5. @Durable (134 likes)

6. @tekdude (120 likes)

7. @Hayen (115 likes)

8. @Mr.Oncoinvest (110 likes)

9. @RakiRebSnem (100 likes)

10. @Astrup (84 likes)

Gratulerer!

[ListeBot]

En fersk aksjonærliste for PHO er tilgjengelig for Insider-medlemmer. Ikke Insider? Les mer og prøv gratis

[ListeBot]

En fersk aksjonærliste for PHO er tilgjengelig for Insider-medlemmer. Ikke Insider? Les mer og prøv gratis

[TekBot]

Photocure announces new US patent for Hexvix

Oslo, Norway February 14, 2020, Photocure ASA (OSE: PHO) is pleased to announce
that the United States Patent and Trademark Office (USPTO) has granted US Patent
No. 10,556,010 covering the use of Blue Light Cystoscopy (BLC[®]) with Hexvix as
…

Vis børsmeldingen

neoadjuvant* therapy in the treatment of bladder cancer in patients who are
scheduled for a cystectomy.

Early stage study results have shown an antitumor effect and induced systemic
immune effects of hexaminolevulinate (HAL) and blue light in an orthotopic model
of rat bladder cancer. Photocure has the intention to further investigate Hexvix
for its therapeutic effect and the patent is a result of Photocure’s continued
focus on securing intellectual property rights for its research results and
pipeline activities.

The patent was issued on 11 February 2020 and will expire in December 2036.

• Neoadjuvant therapy: treatment (such as chemotherapy) administered before
  primary cancer treatment (such as surgery) to enhance the outcome of primary
  treatment

For more information, please contact:
Dan Schneider
President and CEO
Photocure ASA
Tel: + 1-609 759-6515
Email: [email protected]

Erik Dahl
CFO
Photocure ASA
Tel: +4745055000
Email: [email protected]

About Bladder Cancer
Bladder cancer ranks as the sixth most common cancer worldwide with 1 650 000
prevalent cases (5-year prevalence rate), 550 000 new cases and almost 200 000
deaths annually in 2018.[1]

Approx. 75% of all bladder cancer cases occur in men.[1] It has a high
recurrence rate with an average of 61% in year one and 78% over five years.[2]
Bladder cancer has the highest lifetime treatment costs per patient of all
cancers.[3]

Bladder cancer is a costly, potentially progressive disease for which patients
have to undergo multiple cystoscopies due to the high risk of recurrence. There
is an urgent need to improve both the diagnosis and the management of bladder
cancer for the benefit of patients and healthcare systems alike.

Bladder cancer is classified into two types, non-muscle invasive bladder cancer
(NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of
invasion in the bladder wall. NMIBC remains in the inner layer of cells lining
the bladder. These cancers are the most common (75%) of all BC cases and include
the subtypes Ta, carcinoma in situ (CIS) and T1 lesions. In MIBC the cancer has
grown into deeper layers of the bladder wall. These cancers, including subtypes
T2, T3 and T4, are more likely to spread and are harder to treat.[4]
About Hexvix[®]/Cysview[®] (hexaminolevulinate HCl)
Hexvix[®]/Cysview[®] is a drug that is selectively taken up by tumor cells in
the bladder making them glow bright pink during Blue Light Cystoscopy (BLC[TM]).
BLCT with Hexvix[®] /Cysview[®] improves the detection of tumors and leads to
more complete resection, fewer residual tumors and better management decisions.

Cysview[®] is the tradename in the US and Canada, Hexvix[®] is the tradename in
all other markets. Photocure is commercializing Cysview[®] / Hexvix[®] directly
in the US and the Nordic region and has strategic partnerships for the
commercialization of Hexvix[® ]/ Cysview[®] in Europe, Canada, Australia and New
Zealand. Please refer to https://bit.ly/2wzqSQQ for further information on our
commercial partners.

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA

This press release may contain product details and information which are not
valid, or a product is not accessible, in your country. Please be aware that
Photocure does not take any responsibility for accessing such information which
may not comply with any legal process, regulation, registration or usage in the
country of your origin.

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, which makes
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com or www.cysview.com

References

[1] Globocan. Incidence/mortality by
population. Available at: http://globocan.iarc.fr/Pages/bar_pop_sel.aspx
[2] Babjuk M, et al. Eur Urol. 2019; 76(5): 639-657

[3] Sievert KD et al. World J Urol 2009;27:295-300

[4] Bladder Cancer. American Cancer
Society. https://www.cancer.org/cancer/bladder-cancer.html

Kilde

[bamse]

Kan noen forklare hva de har fått patent på ?

[JTHP]

The patent was issued on 11 February 2020 and will expire in December 2036.

Dette var en fin inngang til helgen

[solvoll]

Her er søknaden:
https://patents.google.com/patent/WO2017103283A1/en

[sjog]

Suveren melding

[Fintech]

Mildt sagt

[InVivo]

Dette er jo helt superb for Photocure!

[ufo]

Trodde det het cysview i US?
Hvorledes skal en forstå første avsnitt?

[Savepig]

Cysview er produktkombinasjonen for blålys cystoskopi, mens hexvix er medisinen.

Og dette er terapeutisk bruk, så det er helt nytt.

[eiken]

kreftbehandling/celleforandring

[InVivo]

‘‘The bladder cancer company’’

[ufo]

vil dette også påvirke patenttiden på sysview pga det kan hevdes at behandlingskombinasjonen blir ansett for å være ny. (eller at nå kan en dokumentere terapautisk effekt eller hvorledes virker dette?